Nervous system disorder

1 trials MedDRA PT
1 Registered trials
0 Recruiting
1 Unique sponsors
5 Unique IMPs
1 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (chimeric) 2 substances
Unknown / small molecule 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (human) 1 substance
Phase II: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase II

1 trial
  • Kyverna Therapeutics Inc. Commercial
    KYV-101; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; UBLITUXIMAB
    2024-511168-10-00 4 countries n=88
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Kyverna Therapeutics Inc. Commercial 1 Phase II 0
← All indication landscapes